Arrowstreet Capital’s Mustang Bio MBIO Stock Holding History

Arrowstreet Capital’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-104	Closed	-$249K	–	2439
2020 Q2	$249K	Buy	+104	New	+$243K	﹤0.01%	2139

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Arrowstreet Capital's MBIO Position: Q3 2020 in Review

Arrowstreet Capital sold out of Mustang Bio (MBIO) in Q3 2020, closing a stake of 104 shares — an estimated $249K sold.

Arrowstreet Capital first reported a position in MBIO in Q2 2020 and held it in 1 quarter. The position peaked at $249K in Q2 2020. 75 funds tracked by Wall St. Rank hold MBIO as of Q3 2020.

Arrowstreet Capital reported no remaining Mustang Bio position as of Q3 2020 after selling out during the quarter.
Arrowstreet Capital sold 104 Mustang Bio shares in Q3 2020, an estimated $249K.
Arrowstreet Capital first reported a position in Mustang Bio in Q2 2020 and held it in 1 quarter.
Arrowstreet Capital's Mustang Bio position peaked at $249K in Q2 2020.
75 funds tracked by Wall St. Rank held Mustang Bio as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.